The BeOne Medicines Ltd. (ONC) SEC filings page on Stock Titan provides access to the company’s U.S. regulatory disclosures, including current reports on Form 8‑K and other documents filed with the Securities and Exchange Commission. BeOne is a Switzerland‑domiciled global oncology company whose American Depositary Shares are registered with the SEC, while its ordinary shares trade on the Hong Kong Stock Exchange and it also reports to the STAR Market in Shanghai.
Through its filings, BeOne reports on financial results, material agreements and corporate events. BeOne Medicines Ltd.'s recent Forms 8-K announced quarterly financial results, describing revenue growth driven primarily by BRUKINSA product sales and contributions from TEVIMBRA and in-licensed products. Other 8‑K filings detail a royalty purchase agreement with Royalty Pharma tied to royalty rights on IMDELLTRA (tarlatamab) ex‑China net revenue, as well as the creation of related financial obligations and escrow arrangements.
Additional 8‑K reports cover topics such as the termination of a prior credit facility after arranging new financing, and the appointment and compensation terms of senior research and development leadership. The company also furnishes information about its interim reports filed with the STAR Market, including financial data prepared under China Accounting Standards and summaries of differences from U.S. GAAP.
On Stock Titan, users can review these ONC filings alongside AI‑generated summaries that explain the main points of each document in plain language. This includes highlighting key items in earnings‑related filings, summarizing the structure and implications of material agreements, and pointing out governance or leadership changes disclosed under Item 5.02 of Form 8‑K. Investors can also use the filings page to monitor how BeOne describes its oncology portfolio, collaborations and financial position over time, and to cross‑reference U.S. disclosures with the company’s press releases and non‑U.S. reporting.
Real‑time updates from EDGAR, combined with AI‑assisted overviews, help readers navigate lengthy filings and focus on sections most relevant to their interests, whether they are following BeOne’s hematology and solid tumor programs, its financing arrangements or its multi‑exchange reporting obligations.
BeOne Medicines Ltd. President and COO Wu Xiaobin reported selling 1,484 American Depositary Shares on June 8, 2026 in open-market transactions at prices of $270.55 and a weighted average of $269.3325 per ADS. According to the filing, the sale was effected under a mandatory tax withholding provision tied to the vesting of a restricted share unit award granted to him.
Following these transactions, he holds 40 American Depositary Shares directly, 4,000 American Depositary Shares indirectly through his wife, and 1,197,713 ordinary shares, which include 481 ordinary shares acquired through the company’s 2018 Employee Share Purchase Plan. Each ADS represents 13 ordinary shares.
BeOne Medicines Ltd. Chief Executive Officer John Oyler reported tax-related transactions in American Depositary Shares (ADSs). On June 8, 2026, a total of 4,940 ADSs were sold at weighted average prices of about $270–$271 per ADS. A footnote explains the sale was carried out under a mandatory tax withholding provision connected to the vesting of a previously granted restricted share unit award, rather than a discretionary open-market sale. Each ADS represents 13 Ordinary Shares. Following these transactions, Oyler held no ADSs directly, but continued to have substantial Ordinary Share holdings directly and through various trusts and entities, some of which he disclaims beneficial ownership in the footnotes.
The issuer reported a proposed sale of ADS securities on NASDAQ, filed on 06/08/2026. The filing lists 36,900.64 ADS and references a 06/05/2026 transaction date tied to Restricted Stock Vesting Under a Registered Plan.
ONC submitted a Form 144 notice indicating 871 ADS referenced under its securities information and a restricted stock vesting event on 06/05/2026. The excerpt lists three recent ADS dispositions: 332 ADS on 05/13/2026 for $103,159.04, 332 ADS on 04/08/2026 for $103,447.88, and 341 ADS on 03/11/2026 for $102,300.00.
The issuer reported a Form 144 notice for 1,367 ADS dated 06/05/2026, tied to restricted stock vesting under a registered plan. The form lists Morgan Stanley Smith Barney LLC as the broker and shows transaction details including an amount 368,246.83 and a reference number 54,885,669.
ONC submitted a Form 144 notice reporting a proposed sale of 1,484 ADS. The filing lists the trade date or vesting date as 06/05/2026 and a filing/check date of 06/08/2026. The securities are described as Restricted Stock Vesting Under a Registered Plan and the broker listed is Morgan Stanley Smith Barney LLC with NASDAQ noted as the market.
ONC submitted a Form 144 notice reporting an intended sale of 4,940 ADS relating to Restricted Stock Vesting Under a Registered Plan. The filing lists Morgan Stanley Smith Barney LLC Executive Financial Services as the broker and shows dates 06/05/2026 and 06/08/2026.
BeOne Medicines Ltd. director Yi Qingqing reported a small share disposition linked to equity compensation. On June 1, 2026, Yi disposed of 235 American Depositary Shares of BeOne Medicines at $279.13 per ADS. According to the disclosure, this sale was carried out under a mandatory tax withholding provision in Yi’s restricted share unit (RSU) agreement in connection with RSU vesting, rather than as a discretionary open-market trade. Following the transactions reported, Yi holds 24,271 Ordinary Shares directly, reflecting a continuing equity stake in the company.
BeOne Medicines Ltd. director Alessandro Riva reported a small tax‑related share sale. On 2026-05-22, he sold 212 American Depositary Shares of BeOne Medicines in an open-market transaction at an average price of $309.5142 per ADS. A footnote explains the sale was mandated under a tax withholding provision tied to the vesting of a restricted share unit award, meaning it was executed to cover tax obligations rather than as a discretionary portfolio move. Each American Depositary Share represents 13 Ordinary Shares. After these transactions, a holding entry shows Riva with 54,184 Ordinary Shares held directly.